RATIONALE AND OBJECTIVES: Behavioral, neurochemical and pharmaco-EEG profiles of a new synthetic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats were examined. MATERIALS AND METHODS: Locomotor effects, prepulse inhibition (PPI) of acoustic startle reaction (ASR), dopamine and its metabolite levels in nucleus accumbens (NAc), EEG power spectra and coherence in freely moving rats were analysed. Amphetamine was used as a reference compound. RESULTS: 2C-B had a biphasic effect on locomotion with initial inhibitory followed by excitatory effect; amphetamine induced only hyperlocomotion. Both drugs induced deficits in the PPI; however they had opposite effects on ASR. 2C-B increased dopamine but decreased 3,4-dihydroxyphenylacetic acid (DOPAC) in the NAc. Low doses of 2C-B induced a decrease in EEG power spectra and coherence. On the contrary, high dose of 2C-B 50 mg/kg had a temporally biphasic effect with an initial decrease followed by an increase in EEG power; decrease as well as increase in EEG coherence was observed. Amphetamine mainly induced an increase in EEG power and coherence in theta and alpha bands. Increases in the theta and alpha power and coherence in 2C-B and amphetamine were temporally linked to an increase in locomotor activity and DA levels in NAc. CONCLUSIONS: 2C-B is a centrally active compound similar to other hallucinogens, entactogens and stimulants. Increased dopamine and decreased DOPAC in the NAc may reflect its psychotomimetic and addictive potential and monoaminoxidase inhibition. Alterations in brain functional connectivity reflected the behavioral and neurochemical changes produced by the drug; a correlation between EEG changes and locomotor behavior was observed.

Prague Psychiatric Center Ústavní 91 181 03 Bohnice Prague 8 Czech Republic

Zobrazit více v PubMed

Neuropsychopharmacology. 1992 Aug;7(1):15-31 PubMed

Fundam Clin Pharmacol. 2007 Dec;21(6):567-74 PubMed

Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):473-5 PubMed

Sleep. 1999 Feb 1;22(1):11-31 PubMed

Pharm World Sci. 2004 Apr;26(2):110-3 PubMed

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Nov 25;811(2):143-52 PubMed

Schizophr Bull. 2008 Sep;34(5):974-80 PubMed

Psychopharmacology (Berl). 1995 Apr;118(3):295-304 PubMed

Addict Biol. 2005 Dec;10(4):321-3 PubMed

Psychopharmacology (Berl). 2006 Jul;186(4):579-86 PubMed

Chem Res Toxicol. 2001 Sep;14(9):1203-8 PubMed

J Med Toxicol. 2005 Dec;1(1):22-5 PubMed

Acta Neurobiol Exp (Wars). 1973;33(4):771-89 PubMed

Neuroscience. 2007 Jul 13;147(3):833-41 PubMed

Psychopharmacology (Berl). 1999 Feb;142(1):85-94 PubMed

Physiol Behav. 1994 Nov;56(5):963-8 PubMed

Pharmacol Biochem Behav. 1977 Apr;6(4):427-31 PubMed

Toxicology. 2005 Jan 5;206(1):75-89 PubMed

Electroencephalogr Clin Neurophysiol. 1986 Aug;64(2):123-43 PubMed

Psychopharmacology (Berl). 1982;77(2):179-85 PubMed

Life Sci. 1986 Sep 22;39(12):1051-8 PubMed

Behav Brain Res. 2007 Feb 27;177(2):214-26 PubMed

Cereb Cortex. 2006 Mar;16(3):328-36 PubMed

Psychopharmacology (Berl). 1987;93(3):286-91 PubMed

Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):588-96 PubMed

Prog Neurobiol. 1999 Oct;59(2):107-28 PubMed

Synapse. 1997 Jan;25(1):30-6 PubMed

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):293-4 PubMed

Behav Pharmacol. 2000 Jun;11(3-4):185-204 PubMed

Science. 1987 May 29;236(4805):1110-3 PubMed

Neuropsychobiology. 2011;63(4):202-18 PubMed

Br J Pharmacol. 2002 Jun;136(4):510-9 PubMed

Neuroscience. 1997 Jan;76(2):541-55 PubMed

Eur Neuropsychopharmacol. 2007 May-Jun;17(6-7):483-91 PubMed

Neuroscience. 1992;46(1):49-56 PubMed

Pharmacol Biochem Behav. 2011 Mar;98(1):130-9 PubMed

Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54 PubMed

Neurology. 2004 Oct 12;63(7 Suppl 2):S32-5 PubMed

Sleep. 1989 Feb;12(1):13-21 PubMed

Psychopharmacology (Berl). 1979 Sep;65(1):35-40 PubMed

Pharmacopsychiatry. 1998 Jul;31 Suppl 2:73-9 PubMed

IEEE Trans Biomed Eng. 1986 Jun;33(6):550-9 PubMed

Neuropsychobiology. 1988;19(2):116-20 PubMed

Behav Brain Res. 1997 Dec;89(1-2):35-49 PubMed

Sleep. 1989 Feb;12(1):60-7 PubMed

Clin Electroencephalogr. 2003 Apr;34(2):39-53 PubMed

Forensic Sci Int. 2005 Mar 10;148(2-3):131-7 PubMed

Psychopharmacology (Berl). 2008 Jan;196(1):51-62 PubMed

Neuropsychopharmacology. 2003 Apr;28(4):640-50 PubMed

Psychopharmacology (Berl). 2001 Jul;156(2-3):194-215 PubMed

NIDA Res Monogr. 1989;94:101-26 PubMed

Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12304-8 PubMed

Gen Pharmacol. 1992 Nov;23(6):1139-42 PubMed

Behav Pharmacol. 1996 Nov;7(6):551-559 PubMed

Psychopharmacol Commun. 1975;1(1):93-8 PubMed

J Psychopharmacol. 2012 Jul;26(7):1026-35 PubMed

Pharmacol Biochem Behav. 2004 Dec;79(4):751-60 PubMed

Neuro Endocrinol Lett. 2007 Dec;28(6):781-8 PubMed

Physiol Behav. 2005 Nov 15;86(4):546-53 PubMed

Eur J Pharmacol. 2001 Jul 13;424(1):27-36 PubMed

J Psychoactive Drugs. 1986 Oct-Dec;18(4):305-13 PubMed

Psychopharmacology (Berl). 1989;98(3):297-303 PubMed

Neuropsychopharmacology. 1998 May;18(5):339-51 PubMed

Synapse. 1998 Jun;29(2):142-7 PubMed

Pharmacol Biochem Behav. 1988 Jun;30(2):489-92 PubMed

J Anal Toxicol. 1999 May-Jun;23(3):227-8 PubMed

Pharmacol Biochem Behav. 1989 Apr;32(4):835-40 PubMed

J Pharmacol Exp Ther. 2007 Jun;321(3):1054-61 PubMed

Neuroscience. 2004;124(2):481-8 PubMed

Pharmacol Biochem Behav. 1988 Jul;30(3):597-601 PubMed

Forensic Sci Int. 2001 Sep 15;121(1-2):47-56 PubMed

Chem Res Toxicol. 2001 Sep;14(9):1139-62 PubMed

Psychopharmacology (Berl). 2005 Jul;180(3):427-35 PubMed

Leg Med (Tokyo). 2009 Apr;11 Suppl 1:S429-30 PubMed

Toxicol Lett. 2008 Apr 21;178(1):29-36 PubMed

Behav Pharmacol. 2005 Mar;16(2):127-30 PubMed

Lakartidningen. 2008 Apr 16-22;105(16):1199-200 PubMed

Br J Psychiatry. 2003 Feb;182:97-100 PubMed

Forensic Sci Int. 2007 Aug 6;170(2-3):94-9 PubMed

J Chromatogr A. 2011 May 27;1218(21):3382-91 PubMed

Sci Justice. 2002 Oct-Dec;42(4):223-4 PubMed

Pharmacol Biochem Behav. 2007 Oct;87(4):453-61 PubMed

Neuropsychopharmacology. 1999 May;20(5):424-33 PubMed

Alcohol Health Res World. 1997;21(2):101-6 PubMed

Underlying pharmacological mechanisms of psilocin-induced broadband desynchronization and disconnection of EEG in rats

Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats-pharmacokinetics, effects on behaviour and thermoregulation

Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity

Electrical Source Imaging in Freely Moving Rats: Evaluation of a 12-Electrode Cortical Electroencephalography System

Behavioural, Pharmacokinetic, Metabolic, and Hyperthermic Profile of 3,4-Methylenedioxypyrovalerone (MDPV) in the Wistar Rat

Pharmacokinetic, Ambulatory, and Hyperthermic Effects of 3,4-Methylenedioxy-N-Methylcathinone (Methylone) in Rats

Synthetic Aminoindanes: A Summary of Existing Knowledge

Mephedrone (4-Methylmethcathinone): Acute Behavioral Effects, Hyperthermic, and Pharmacokinetic Profile in Rats

The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat